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INTRODUCTION 
Exercise testing of patients with known heart disease may be 
conducted to assess the adequacy of conventional therapy, the 
overall prognosis for a patient, and to provide guidelines for an 
appropriate level of daily activity (Skinner, p. 211). For 
cardiac patients, the exercise test results are not for diagnosis 
of heart disease, but are used to determine the functional 
significance of the disease (Skinner, p. 216). 
There is concordance among exercise test clinicians that 
symptom-limited maximal exercise testing should be elected over 
sub-maximal exercise testing in the cardiovascular assessment of 
coronary heart disease patients (Skinner, p. 214). Symptom-
limited maximal testing is especially favored when the purpose of 
the test is to determine a patients exercise capacity. Sub-
maximal testing is not of a great deal of value to clinicians 
when testing heart disease patients because these patients 
maximal, or peak, heart rates can not be accurately estimated. 
Peak heart rates in patients with disease are generally lower 
than healthy people of the same age. The standard deviation for 
maximal heart rates in heart patients is more than double the 9-
11 beats per minute in healthy individuals (Skinner, p. 214). 
For some patients, certain contraindications to exercise 
testing may apply. For those, the benefit of testing may be 
overshadowed by the risks it may present. These 
contraindications must be addressed by a physician before actual 
testing may occur. A table of contraindications may be found in 
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-Appendix A. It should be noted that some contraindications may 
not apply where a patient is being tested for specific reasons. 
These reasons may include a recent myocardial infarction, 
surgical procedure, or an effort by physicians to determine 
appropriate medical prescription (ACSM, p. 58). 
Symptom-limited maximal testing is very much called for in 
heart disease patients. The concept of symptom-limited maximal 
testing is based upon the notion that a patient will continue a 
monitored bout of exercise testing until the patient must stop. 
Reasons a patient would stop performing an exercise test include 
fatigue, or symptoms and/oT signs indicate that further testing 
is not warranted. Exercise test termination criteria varies 
according to three things: clinical status of the patient, the 
primary purpose of the test, and the general test environment 
(Skinner, p. 214). In a patient who recently had a myocardial 
infarction, a more conservative interpretation of the test 
termination criteria should be employed (Skinner, p. 214). If 
the purpose of the test is to authorize a patient to return to a 
highly demanding job, or to participate in a high level of 
exercise, more aggressive test interpretation should take place 
(Skinner, p. 215). Finally, a very liberal attitude may be 
employed in a medical centsr with experienced clinicians and 
nearby medical facilities (Skinner, p. 215). 
Patients with disease are often prescribed medications to 
care for their respective diseases. It is the clinicians job to 
be informed of the patients medical history (ACSM, p. 150). By 
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knowing all the details, a clinician can give a more accurate and 
safe exercise prescription. Medications can give false positive 
or negative test results, and can alter physiological responses 
to exercise. 
Sometimes, exercise tests may need to be terminated by the 
exercise test technician based on signs or symptoms provoked in 
the individual by an exercise test. Symptom-limited maximal 
exercise testing of patients with heart disease should be 
terminated when the patient demonstrates significant fatigue, or 
signs and symptoms indicate the test should not be continued. 
Further diagnostic evaluation of the patient is warranted if 
symptoms or signs indicate the test should be discontinued (ACSM, 
p. 126). Continuing testing after test termination has been 
attained will not provide any additional useful information for 
the clinician, and may endanger the health of the patient by 
increasing their risk of medical complications. The following is 
an explanation of exercise test termination criteria in patients 
with known heart disease (Skinner, p. 215). 
SYMPTOMS 
Symptoms indicating the termination of an exercise test is 
the most sUbjective category of exercise test termination 
criteria. This category of criteria is heavily regulated by 
patient input. The patients own perception of how they feel 
should be questioned by the clinician frequently during the 
exercise test. It is the clinicians duty to evaluate the 
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patients input, and make appropriate decisions based on this 
input. The conditions associated in this area of exercise test 
termination criteria are angina, lightheadedness, dyspnea, 
fatigue, muscle pain, and nausea (Skinner, p. 215). 
The patient may indicate chest pain during the exercise 
test. This chest pain, or angina pectoris, may be defined as a 
crushing, heavy feeling in the center of the chest, and may 
include pain down the left arm, neck, or jaw (ACSM, p. 26). 
Increasing angina described as severe, or the most severe pain 
ever felt by the patient indicates a termination of the exercise 
test (Skinner, p. 215). The pain indicated by the patient in 
this situation correlates to a grade 3 or 4 on the angina scale, 
shown here (ACSM, p. 73): 
Angina Scale 
1+ light, barely 
noticeable 
2+ moderate, bothersome 
3+ severe, very 
uncomfortable 
4+ most severe pain 
ever experienced 
Angina may indicate ischemia, and may be present along with 
ECG signs of ST segment depression and evidence of a myocardial 
infarction. Other signs, such as dizziness, ataxia, nausea, 
vomiting, and impaired consciousness may also be present (Nieman, 
p. 92). 
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Severe dyspnea, or shortness of breath, indicated by the 
patient also calls for exercise test termination (Skinner, p. 
215). Some high grades of dyspnea may be evident to the 
clinician. The following dyspnea scale may be used by the 
clinician to determine the degree of dyspnea (ACSM, p. 73): 
Dyspnea Scale 
+1 mild, not noticeable 
to the clinician 
+2 mild, some 
difficulty, 
noticeable 
+3 moderate difficulty, 
can continue 
+4 severe difficulty, 
patient can't 
continue 
Additional symptomatic signals of exercise test termination 
are fainting/lightheadedness, severe fatigue, severe skeletal 
muscle pain, and nausea/vomiting (Skinner, p. 215). 
Lightheadedness and nausea may indicate ischemia and be 
accompanied by ischemic ECG signals (Nieman, p. 92). Severe 
fatigue and skeletal muscle pain make it difficult for patients 
to simply perform the test, thus, they contraindicate further 
progress of the test. 
CLINICAL SIGNS 
Clinical signs indicating that an exercise test should be 
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-terminated are indications by the patient that will be visible to 
- the clinician. These physical signs may dictate to the clinician 
that the patient cannot co-ntinue the test. 
-
-
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These clinical signs are included in the following table 
(Skinner, p. 215): 
CLINICAL SIGHS 
Pallor 
Cold, moist skin 
Cyanosis 
Staggering gait ataxia 
Confusion 
Blank stare 
Clinical signs for exercise termination may indicate low 
cardiac output states. These signs may be accompanied by low 
blood pressure, or hypotension, and dizziness. Electrocardiograph 
signs that may be present are arrhythmias, tachycardia, 
bradycardia, premature atrial contractions, and premature 
ventricular contractions (Nieman, p. 92). 
ELECTROCARDIOGRAM SIGHS 
Ischemia 
Ischemia is a condition in which the oxygen demands of the 
myocardium exceed the oxyg€n supply to the myocardium, because of 
inadequate myocardial blood flow (ACSM, p. 25). This situation 
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Mobitz Type II is less common than Type I. Mobitz Type II 
is characterized by an abruptly dropped QRS complex with no 
change to the PR intervals. The QRS complexes may also be 
prolonged and widened (Johnson & Swartz, p. 63). This type of 
block is more serious than Type I because it may be a predecessor 
to third degree atrioventricular block (complete heart block) . 
Third degree atrioventricular block is a serious condition 
in which atrial impulses are not transmitted to the ventricles. 
On ECG tracings, this condition will display atrial and 
ventricular rates which ar"e not connected. "This condition is 
called atrioventricular dissociation. Third degree 
atrioventricular block is very serious because the ventricular 
rate, controlled by the AV node in this condition, is too slow to 
effectively pump blood through the cardiovascular system (Johnson 
& Swartz, p. 64). 
Bundle branch blocks are abnormalities in conduction that 
disrupt the normal route of ventricular depolarization. This 
disruption will cause a prolonged QRS complex, and an abnormal 
QRS morphology (Johnson & Swartz, p. 67). The following is a 
table of ECG indications of bundle branch blocks (Dwyer, p. 18): 
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Right Bundle Branch Block 
-QRS wider 0.12 seconds 
-R, R', or M pattern in V1 
-right axis deviation 
-deep S waves in V6 
-T wave inversion in V1-V3 
Le~t Bundle Branch Block 
-QRS wider 0.12 seconds 
-wide notched R wave in 
V6 and I 
-wide QS wave in V1 
-T wave inversion 
in V6 and I 
-absence of Q waves 
in V6 and I 
-approximately 50% of 
all LBBB have 
left axis deviation 
Right bundle branch block is usually fixed, but may be 
intermittent at rapid heart rates. It is not uncommon and can be 
seen in healthy or older individuals (Dwyer, p. 19). 
Left bundle branch block is more serious, and can also be 
fixed or intermittent. It is usually a sign of organic heart 
disease, and it can be seen in individuals with hypertension, or 
valvular anomalies. Left bundle branch block is also serious 
because the presence of it makes the determination of ischemic 
changes, and myocardial infarction, on the EeG impossible (Dwyer, 
p. 19). The different conduction disturbances are shown in 
appendix B. 
Supraventricular Arrhythmias Occurring With Exercise 
There are two types of supraventricular arrhythmias to be 
discussed: atrial fibrillation, and supraventricular 
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tachycardia. 
Atrial fibrillation is characterized by the absence of P 
waves. The P waves are not present because the atria are 
contracting 400 to 500 times per minute. These numerous 
contractions are weak and incomplete, and a wavy and undulating 
baseline made up of F waves may be seen (Dwyer, p. 24). 
Ventricular rates are generally between 120-200 beats per minute, 
and R-R intervals and QRS complexes may appear irregular. Atrial 
fibrillation may be serious because of a decreased cardiac 
output, and a tendency for the static blood in the atria to begin 
clotting. The risk of the blood clot, or thrombus, to pass into 
the circulatory system is real. 
Supraventricular, or atrial, tachycardias are a group of 
arrhytmias that occur above the ventricles. Atrial tachycardia 
is a run of three atrial premature contractions in a row. Atrial 
premature contractions are characterized by P waves that fall 
early in the cardiac cycle, and are different in configuration. 
The term paroxysmal is used to describe atrial tachycardia 
because of its sudden onset and termination. In atrial 
tachycardia, the ventricular rate will generally fall between 
150-250 beats per minute. Although the QRS complex will not 
generally be affected, P waves will occasionally superimpose on T 
waves (Johnson & Swartz, p. 36). Supraventricular tachycardias 
are not generally serious and can be caused by a variety of 
things including emotions, stress, stimulants, or fatigue (Dwyer, 
p. 25). Atrial arrhythmias are illustrated in appendix B. 
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Ventricular Arrhythmias 
Ventricular arrhythmias are caused by ectopic impulses, that 
cause the normal route of depolarization to be bypassed, and 
prevents the simultaneous depolarization of the ventricles 
(Johnson & Swartz, p. 47). This category of arrhythmias includes 
ventricular premature contractions, ventricular tachycardia, and 
ventricular fibrillation. 
Ventricular premature contractions fall early in the cardiac 
cycle. They are shown on the electrocardiogram by early, wide 
QRS complexes greater than or equal to 0.12 seconds. This 
condition may frequently include a full compensatory pause, 
which is signified by the duration of two cardiac cycles with the 
ventricular premature contraction; the same in length as two 
normal cardiac cycles. Another event that may be seen during a 
ventricular premature contraction is a fusion beat. This is a 
"fusion" of a normal beat and a ventricular premature contraction 
beat. Ventricular premature contractions are the most common of 
all arrhythmias. An occasional ventricular premature contraction 
is normal in everyone. They are considered serious when they 
occur frequently, in greater than 30% of all complexes. 
Ventricular tachycardia is a run of ventricular premature 
contractions; three or more in a row. (Johnson & Swartz, p. 52). 
The characteristics of ventricular tachycardia are shown here: 
-bizarre, wide QRS complex wider than 0.12 seconds 
-atrioventricular dissociation 
-regular ventricular rate at 140-200 beats per minute 
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-possible fusion beats 
-possible capture (Dressler) beats (normal QRS 
complex in a run of ventricular premature 
contractions) 
ventricular tachycardia may be serious because the rapid 
ventricular rate does not allow adequate filling time of the 
ventricles, thus cardiac output is decreased. This hypotension 
can lead to cardiac arrest (Johnson & Swartz, p. 54). 
ventricular fibrillation is characterized by no recognizable 
P waves, QRS complexes, or T waves. This condition is often 
present in individuals who are at high risk for heart disease, or 
have heart disease (Johnson & Swartz, p. 55). This condition is 
serious, and may signal genetic conduction abnormalities. 
Cardioversion, or defibrillation, is necessary in treatment of 
ventricular fibrillation because of the potential of cardiac 
arrest or sudden death (Dwyer, p. 27). The various ventricular 
arrhythmias are shown in appendix B. 
MEDICATIONS 
Patients with heart disease are frequently prescribed 
medications to manage their respective conditions. These 
medications may alter cardiorespiratory and/or metabolic 
responses to the exercise test. The exercise test technician 
should be aware of any patients' medication history before 
testing (ACSM, p. 150). 
Exercise testing is most efficient when a patient is taking 
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their prescribed medicine. It is advisable for a patient to have 
a new exercise test administered with a dramatic change in 
medication prescription (ACSM, p. 150). Classes of medications 
that may alter exercise testing are nitrates, beta-blockers, 
calcium channel blockers, vasodialators, and digitalis (Dwyer, p. 
31) . 
Nitrates 
Nitrates are a popular type of medication to relieve angina. 
These medications may elicit post exercise hypotension, and may 
increase resting and exercise heart rates (Dwyer, p. 32). 
Ischemia during exercise may be prevented or delayed due to this 
medication. The exercise capacity of patients taking nitrates 
may increase in patients with angina, or be unaffected in 
patients without angina. In patients with congestive heart 
failure, exercise capacity may increase, or not be affected 
(ACSM, p. 276). 
Beta-Blockers 
The most commonly used heart medications are beta-blockers. 
They relieve angina and hypertension and are used for patients of 
congestive heart failure. Because beta-blockers block the 
sympathetic receptor on the heart, heart rate and blood pressure 
is lowered. Beta-blockers may also cause fatigue (Dwyer, p. 32). 
Despite these factors, symptom-limited maximal testing can still 
be used for exercise prescription. Of clinical value during 
testing is the intensity level or heart rate at the onset of 
symptoms (Skinner, p. 217). In patients with angina, beta-
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blockers will increase exercise capacity, but in patients without 
angina, exercise capacity will decrease or remain unchanged 
(ACSM, p. 276). Another effect of beta-blockers is to delay the 
onset of or prevent ischemia (ACSM,p. 276). 
Calcium Channel Blockers 
Calcium channel blockers are a class of medications to help 
relieve angina, hypertension, and congestive heart failure. 
Different calcium channel blockers produce different effects. 
The generic medication Nifedipine may elicit different side 
effects than most other types of calcium channel blockers. 
Nifedipine will increase resting and exercise heart rates, while 
other types of calcium channel blockers will decrease resting and 
exercise heart rates. 
Some general effects of all calcium channel blockers are a 
decrease in both resting and exercise blood pressure. Calcium 
channel blockers may delay or prevent ischemia, and increase 
exercise capacity of patients with angina (ACSM, p. 276). 
Vasodilators 
Vasodilators are not widely used medications. The primary 
purpose of this drug is td relieve hyperten~ion (Dwyer, p. 32). 
There are three categories of vasodilators; these are peripheral, 
alpha-adrenergic blockers, and anti-adrenergic agents without 
selective blockade of peripheral receptors. 
Peripheral vasodilators may cause an increase in resting and 
exercise heart rates, and a decrease in blood pressure. Exercise 
capacity probably will not change, except in patients with 
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congestive heart failure, and then in may increase (ACSM, p. 
276) . 
Alpha-adrenergic blockers will not have many side effects. 
One effect they will have though are to decrease resting and 
exercise blood pressure (ACSM, p. 276). 
Alpha-adrenergic agents without selective blockade of 
peripheral receptors will decrease or unaffect rest and exercise 
heart rates. Blood pressure may decrease, and exercise capacity 
will probably remain unchanged (ACSM, p. 276). 
Digitalis 
Digitalis is the oldest cardiovascular medication 
prescribed, and it is used for patients of congestive heart 
failure (Dwyer, p. 34). Heart rate may decrease in patients with 
atrial fibrillation while taking this medication. 
Electrocardiograph changes include non-specific ST-T wave changes 
at rest. When exercising, ST segment depression may occur (ACSM, 
p. 276). Digitalis may cause a lot of difficulty when 
interpreting exercise tests. The ECG cannot be interpreted when 
there are ST segment changes while on digitalis. If ischemia is 
a likely risk, and must be documented, the drug should be 
discontinued for three weeks, and the exercise test performed 
after that time. However, if the ECG shows a normal ST segment, 
it should be interpreted as normal, or negative (Skinner, p. 
217) . 
A list of generic medication names for each class of 
medications can be found in appendix C. 
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CONCLOSION 
Two additional termination criteria exist; they are patient 
requests to stop the exercise test, and the ECG monitoring system 
fails (Skinner, p. 215). As trivial as these may sound, to 
continue testing after these endpoints is not ethical, and could 
endanger the health of the patient. 
In testing patients with heart disease, the clinician 
will encounter various degrees of dysfunction. The clinician is 
to determine the degree of impairment, and provide a prognosis 
for the patient including such events as reinfarction, cardiac 
arrest, heart failure, and the patients functional capacity 
(ACSM, p. 122). 
The prognosis derived from exercise testing will be used by 
the clinician to determine the levels of exercise training, type 
of training best suited for the patient, intensity of training, 
. . 
and the degree of medical supervision appropriate for the patient 
(ACSM, p.122). 
When testing patients with known heart disease, all test 
termination criteria should be evaluated. There is occasionally 
a tendency for exercise test technicians to focus only on one or 
two signs or symptoms, and ignore equally significant others 
(Skinner, p. 215). Comprehensive monitoring of patients will 
increase the reliability and clinical value of exercise test 
results, and will help to minimize complications resulting from 
the testing (Skinner, p. 216). The more severe the case of the 
disease a patient has, the more attention should be given to each 
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of the signs or symptoms elicited in a patient by the exercise 
test (Skinner, p. 216). 
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APPENDIX A 
Absolute contraindications to Exercise Testing 
*recent ECG change indicating infarction or an acute cardiac 
event 
*recent complicated myocardial infarction 
*unstable angina 
*uncontrolled ventricular dysrhythmia 
*atrial dysrhythmia compromising cardiac function 
*third degree atrioventricular block 
*acute congestive heart failure 
*severe aortic stenosis 
*dissecting aneurysm 
*myocarditis or pericarditis 
*thrombophlebits or intracardiac thrombi 
*recent systemic or pulmonary embolus 
*acute infection 
*psychosis 
Relative contraindications to Exercise Testing 
*resting diastolic blood pressure >120 mm Hg or, 
resting systolic blood pressure >200 mm Hg 
*moderate valvular heart disease 
*hypokalemia, hypomagnesemia 
*fixed-rate pacemaker (rare) 
*frequent or complex ventricular ectopy 
*ventricular aneurysm 
*cardiomyopathy 
*uncontrolled metabolic disease 
*chronic infectious disease 
*neuromuscular, musculoskeletal, or rheumatoid disorders worsened 
by exercise 
*advanced or complicated pregnancy 
(ACSM, p. 59) 
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ventricular premature contraction 
ventricular tachycardia 
I --- ---- ... 
ventricular fibrillation 
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CLASS 
*Nitrates 
*Beta-Blockers 
APPENDIX C 
Medication Names 
GENERIC NAME 
*Isosorbide dinitrate 
*Nitroglycerin 
*Acebutolol 
*Atenolol 
*Metoprolol 
*Wadolol 
*pindolol 
*Propranolol 
*Timolol 
*Calcium Channel Blockers *Diltiazem 
*Nifedipine 
*Nitrendipine 
*Vasodialators 
*Digitalis 
*Nonadrenergic 
*Hydralazine 
*Minoxidil 
*Prazosin 
*Terazosin 
*Clonidine 
*Guanabenz 
*Guanethidine 
*Guanfacine 
*Methyldopa 
*Reserpine 
*Digoxin 
(ACSM, p. 273-274) 
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